

CITATION REPORT

List of articles citing

Consensus Recommendations to Optimize Testing for New Targetable Alterations in Non-Small Cell Lung Cancer

DOI: 10.3390/currenco129070396
Current Oncology, 2022, 29, 4981-4997.

Source: <https://exaly.com/paper-pdf/148981271/citation-report.pdf>

Version: 2024-04-25

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
5	Disparate Time-to-Treatment and Varied Incidence of Actionable Non-Small Cell Lung Cancer Molecular Alterations in British Columbia: A Historical Cohort Study. 2023 , 30, 145-156		0
4	Case report: olaparib use in metastatic lung adenocarcinoma with BRCA2 pathogenic variant. 2022 , 8, a006223		0
3	Minimizing Sample Failure Rates for Challenging Clinical Tumor Samples. 2023 ,		0
2	Next-generation sequencing of non-small cell lung cancer at a Quebec health care cancer centre. 2023 , 35, 100696		0
1	State of the Art of Pathologic and Molecular Testing. 2023 ,		0